Jolt Health Inc. focuses on licensing technologies related to pharmaceutical-grade therapeutics in Canada, primarily in the sexual health sector. The company faces significant concerns, including a low current ratio of 0.01, indicating severe liquidity issues, and a negative return on assets of -34.4%, reflecting operational inefficiencies. With a market cap of only $445.51K, the valuation appears low, raising questions about investor confidence and future growth potential. Overall, while the niche focus may offer opportunities, the financial health raises red flags for potential investors.
Loading financial metrics...
Company has $53 in cash but burned $85K last quarter. At this burn rate, only 0.0 quarters of runway remain without additional financing.
Company posted a loss of $-1.0M over the last year, representing Infinity% of revenue.
Debt of $98K is 1849.1x the company's cash position of $53.
Operating cash flow has been negative for 3 consecutive quarters, burning $338K over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q2 (June 30, 2025)